Showing 1441-1450 of 23116 results for "".
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
https://reachmd.com/programs/global-neurology-academy/beyond-the-primary-endpoint-what-oceanic-stroke-subtype-analyses-reveal-about-asundexians-potential/54416/Dive into stroke subtype data from OCEANIC-STROKE to see how asundexian's effects vary across clinically distinct patient populations.Real-World Impact of Evolocumab on MACE Reduction in ASCVD
https://reachmd.com/clinical-practice/cardiology/real-world-impact-of-evolocumab-on-mace-reduction-in-ascvd/39991/Review real-world data on evolocumab and its association with reduced MACE in patients with established atherosclerotic cardiovascular disease.Effect of Vericiguat on Heart Failure Hospitalization Events in Ambulatory Patients With HFrEF: VICTOR Trial Prespecified Analysis
https://reachmd.com/clinical-practice/cardiology/effect-of-vericiguat-on-heart-failure-hospitalization-events-in-ambulatory-patients-with-hfref-victor-trial-prespecified-analysis/37614/Effect of Vericiguat on Heart Failure Hospitalization Events in Ambulatory Patients With HFrEF: VICTOR Trial Prespecified AnalysisEfficacy of Obicetrapib Across Diverse Background Lipid-Lowering Regimens: Pooled BROADWAY & BROOKLYN Analyses
https://reachmd.com/clinical-practice/cardiology/efficacy-of-obicetrapib-across-diverse-background-lipid-lowering-regimens-pooled-broadway-brooklyn-analyses/36582/Efficacy of Obicetrapib Across Diverse Background Lipid-Lowering Regimens: Pooled BROADWAY & BROOKLYN AnalysesVICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
https://reachmd.com/clinical-practice/cardiology/victor-trial-results-vericiguat-efficacy-and-safety-across-baseline-background-therapy-in-contemporary-ambulatory-patients-with-hfref/39253/VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEFVICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
https://reachmd.com/clinical-practice/cardiology/victor-prespecified-analysis-results-vericiguat-effects-on-mortality-in-ambulatory-patients-with-hfref/39252/VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEFCETP Inhibition and Obicetrapib: A New Era in Lipid Management
https://reachmd.com/clinical-practice/cardiology/cetp-inhibition-and-obicetrapib-a-new-era-in-lipid-management/37123/CETP Inhibition and Obicetrapib: A New Era in Lipid ManagementOCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
https://reachmd.com/programs/global-neurology-academy/oceanic-stroke-results-asundexian-for-secondary-stroke-prevention-after-acute-non-cardioembolic-stroke-or-high-risk-tia/54141/Explore key findings from OCEANIC-STROKE on asundexian’s role in reducing recurrent stroke without added bleeding risk.Medical Care on the Job: Physician Assistants in Occupational Medicine
https://reachmd.com/programs/clinicians-roundtable/medical-care-on-the-job-physician-assistants-in-occupational-medicine/5159/How do employees working in large facilities know it's safe to return to work after being injured on the job? More than likely they must get clearance from one of the 2000 physician assistants working in occupational medicine across the country. Jack Lasoski, director of health services for the UnitHypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
https://reachmd.com/clinical-practice/cardiology/hypertrophic-cardiomyopathy-overcoming-practical-barriers-to-treatment-in-the-era-of-myosin-inhibitors/56414/Dive into practical barriers to myosin inhibitor use in HCM and learn strategies to support timely initiation and access for eligible patients.